QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Microcystic lymphatic malformations

Economic burden and healthcare resource utilization

2 evidence topics · 2 sources

Pediatric lymphatic malformations: United States inpatient burden, study years

“years 2000, 2003, 2006, and 2009” (opens the source at this quote in a new tab)

Pediatric lymphatic malformations: United States inpatient burden, hospital charges

“Average total charges per admission were $30,995” (opens the source at this quote in a new tab)